Emerg Infect DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for Disease Control and Prevention21192859320463210-075010.3201/eid1701.100750DispatchSerodiagnosis of Primary Infections with Human Parvovirus 4, FinlandLahtinenAnneKiveläPiaHedmanLeaKumarArunKanteleAnuLappalainenMaijaLiitsolaKirsiRistolaMattiDelwartEricSharpColinSimmondsPeterSöderlund-VenermoMariaHedmanKlausAuthor affiliations: University of Helsinki, Helsinki, Finland (A. Lahtinen, L. Hedman, A. Kumar, A. Kantele, M. Söderlund-Venermo, K. Hedman);Helsinki University Central Hospital, Helsinki (P. Kivelä, L. Hedman, A. Kantele, M. Lappalainen, M. Ristola, K. Hedman);National Institute for Health and Welfare, Helsinki (K. Liitsola);Blood System Research Institute, San Francisco, California, USA (E. Delwart);University of California, San Francisco (E. Delwart);University of Edinburgh, Summerhall, UK (C. Sharp, P. Simmonds)Address for correspondence: Klaus Hedman, Department of Virology, Haartman Institute, University of Finland, Box 21, Haartmaninkatu 3, Helsinki FIN-00014, Finland; email: klaus.hedman@helsinki.fi120111717982

To determine the prevalence of parvovirus 4 infection and its clinical and sociodemographic correlations in Finland, we used virus-like particle–based serodiagnostic procedures (immunoglobulin [Ig] G, IgM, and IgG avidity) and PCR. We found 2 persons with parvovirus 4 primary infection who had mild or asymptomatic clinical features among hepatitis C virus–infected injection drug users.

Keywords: Parvovirusviruseshepatitis C virusHIVantibodiesserodiagnosisprimary infectioninjection drug usersFinlanddispatch

A new member of family Parvoviridae, human parvovirus 4 (PARV4), was identified in plasma of an injection drug user (IDU) with unexplained fatigue, headaches, fever, night sweats, nausea, and diarrhea (1). In PCR studies of blood and postmortem tissues, virus was detected mainly in persons with histories of injection drug use (25). A recent PARV4 immunoglobulin (Ig) G study also showed higher prevalence of antibodies to PARV4 in IDUs and HIV-positive persons who had hemophilia than in HIV-positive men who have sex with men (6). The clinical role of this virus is unknown.

We report virus-like particle–based comprehensive serodiagnosis for PARV4 and determine its occurrence in Finland in 3 diverse population groups. In the highest prevalence group, we comparatively analyzed PARV4 IgG–positive and IgG–negative persons for sociodemographic and behavioral background factors and symptoms by using an HIV risk factor database (7).

The Study

Group 1 (low risk) comprised 115 university students (1 serum sample/student). Group 2 (high risk) comprised 78 HIV IgG–positive IDUs from the Helsinki Cohort Study (8) (151 plasma samples, 1–7 samples/person). Group 3 (high risk) comprised 200 hepatitis C virus (HCV) IgG–positive patients (1 sample/person). Informed consent was obtained from persons in groups 1 and 2 and from 2 patients with primary infections in group 3. The study was reviewed and approved by the Helsinki University Central Hospital Ethics Committee (#281/13/03/01/09 and #469/2001).

Four genomic regions of open reading frame 2 of PARV4 genotype 1 (AY622943) were cloned for baculovirus expression by using PARV4 PCR–positive plasma (1) as initial template. The clone with nt region 3137–5122 (AY622943) and infectivity was constructed with primers PARV4EcoRI_3137: 5′-TATGAATTCATGATTGAGCATGGGG-3′ and PARV4EagI_5122: 5′-TACGGCCGTTACAGCAAATGAGAATAA-3′.

Protein expression and virus-like particle purification were conducted as for human bocavirus (HBoV) (9). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis identified a 73-kDa protein (Figure 1, panel A), which was immunoreactive by Western blotting (10) with 5 known PARV4 IgG–positive serum samples (6) but not with negative serum samples (Figure 1, panel B). Electron microscopy showed spherical particles ≈25 nm in diameter (Figure 1, panel C) that resembled those seen in vivo (11). The capsid protein region is 109 aa longer (N terminally) than that reported by Sharp et al. (6); both constructs assembled into capsids.

Parvovirus 4 (PARV4) virus-like particle (VLP) expression and immunoreactivity, Finland. A) Sodium dodecyl sulfate–polyacrylamide gel electrophoresis of PARV4-like particles in Spodoptera frugiperda armyworm (Sf)9 cells (lane 1), purified VLPs (lane 2), and uninfected Sf9 cells (lane 3). B) Western blotting with PARV4 immunoglobulin (Ig) G–positive serum (lanes 1, 3, and 4) or PARV4 IgG–negative serum (lane 2). Lanes 1 and 2, purified VLPs as antigen; lane 3, Sf9 cells expressing VLPs; lane 4, Sf9 cells expressing glutathione-S-transferase control antigen; lanes M, molecular mass marker. Arrows in panels A and B indicate the PARV4 capsid protein. C) Electron micrograph of purified VLPs. Scale bar = 200 nm.

PARV4 IgG enzyme immunoassay (EIA) was conducted as for HBoV (9). Specific results were obtained by subtracting antigen-free background levels. For IgM EIA, a μ-capture format was used (9). IgG and IgM cutoff values, obtained from group 1 absorbances (mean + 4 × SD), were 0.141 and 0.205, respectively. IgG-avidity EIA was conducted as for HBoV (method A) (12); cutoff values for high and low avidity were 25% and 15%, respectively.

None of the 115 students (group 1) were PARV4 IgG positive, and 1 (0.9%) of 115 was weakly IgM positive (Figure 2, panel A). Sixty-one (78.2%) of 78 HIV-infected patients (group 2) were IgG positive, and 4 (5.1%) of 78 were IgM positive (Figure 2, panel B). Sixty-nine (34.5%) of 200 HCV-infected patients (group 3) were IgG positive, and 3 (1.5%) of 200 were IgM positive (Figure 2, panel C). Previous samples were available for 2 of the IgM-positive patients (A and B) in group 3. These samples showed seroconversion for IgG and an increase in IgG (Table 1).

Parvovirus 4 (PARV4) enzyme immunoassay (EIA) results, Finland. Red dots, immunoglobulin (Ig) M; ×, IgG. Upper dashed line indicates IgM cutoff value (0.205), and lower dashed line indicates IgG cutoff value (0.141). A) Group 1: 115 university students (1 serum sample/person); none positive for PARV4 IgG, and 1 positive for PARV4 IgM. B) Group 2: 78 HIV-infected injection drug users (151 serum samples [1–7 samples/person]). Prevalences of PARV4 IgG and IgM were 78.2% (61/78) and 5.1% (4/78), respectively. C) Group 3: 200 hepatitis C virus–infected patients (1 sample/person). Prevalences of PARV4 IgG and IgM were 34.5% (69/200) and 1.5% (3/200), respectively.

Virologic findings for PARV4 primary infections in 2 patients, Finland*
PatientDate of samplingIgG EIA absorbanceIgM EIA absorbancePCRIgG avidity, %
A
2004 Sep 80.0160.051ND
2006 Mar 14
2.873
0.218
+
17.7
B2006 Mar 130.9501.461+8.9
2006 Apr 61.9460.661+10.1

*PARV4, parvovirus 4; Ig, immunoglobulin; EIA, enzyme inmmunoassay; –, negative; ND, not determined; +, positive.

PARV4 IgG avidity was determined in all persistently (>1 year) IgG-positive persons in group 2 (n = 29). Twenty-eight persons showed high IgG avidity, and 1 showed borderline IgG avidity. All 4 IgM-positive persons had high-avidity IgG, which indicated previous immunity.

In group 3, a second sample from patient A, who showed seroconversion for IgG showed borderline IgG avidity. Patient B showed low IgG avidity in both samples (Table 1).

Groups 2 and 3 were also analyzed for PARV4 DNA by qualitative PCR (13) as modified (94°C for 10 min; 45 cycles at 94°C for 20s, 51°C or 56°C for 20s, and 72°C for 20s; and extension at 72°C for 7 min). Amplicons were subjected to electrophoresis and sequenced. In group 2, all 151 serum samples were PCR negative. In group 3, two patients (A and B) were PCR positive (Table 1).

PARV4 IgG–positive and IgG–negative IDUs (group 2) were compared for demographic and clinical characteristics. PARV4 IgG–positive persons reported more injection of drugs, persistent (>10 y) injection, and lending of injection equipment (Table 2). They also had a more frequent history of imprisonment and unemployment and were less educated. No differences were seen between PARV4 IgG–positive and IgG–negative persons with any symptoms (fever, tiredness, nocturnal sweating, cough, diarrhea, shortness of breath, swallowing complaints, muscle weakness, dizziness, skin abscesses or herpetic lesions, loss of eyesight, or headache) during 6 months before being interviewed.

Characteristics of PARV4 IgG–positive and IgG–negative HIV-infected injection drug users, Finland*
CharacteristicIgG positive, n = 61IgG negative, n = 17p value†
Age, y, median (range)35 (17–61)31 (21–55)0.069
Male sex
44/61 (72)
12/17 (71)
1.000
Main drug was amphetamine‡38/61 (62)10/17 (59)0.786
Duration of injection, y, median (range)10 (0–36)7 (0–30)0.259
Duration of injection >10 y
45/59 (76)
7/17 (44)
0.029
History of imprisonment49/61 (80)9/17 (53)0.031
Education <9 y
52/59 (88)
10/17 (59)
0.011
HCV antibody positive59/60 (98)14/15 (93)0.362
HBsAg positive3/61 (5)3/17 (18)0.114
HBc IgG positive46/60 (77)9/17 (56)0.124
Used antiretroviral therapy§29/61 (48)4/17 (24)0.099
CD4 cell count/µL, median§
303
323
0.168
Present situation
Unstable living conditions (no permanent address)35/59 (60)5/15 (33)0.088
Employed‡
0/53 (0)
3/16 (19)
0.009
Risk behavior
Loaned needles or syringes49/59 (83)9/16 (56)0.040
Borrowed needles or syringes56/58 (97)15/16 (94)0.524
Had sexually transmitted diseases37/57 (65)7/17 (41)0.097
Had commercial sex
18/61 (30)
8/15 (53)
0.127
Risk behavior past 6 mo
Used drugs48/61 (79)8/17 (47)0.016
Used injection drugs46/61 (75)8/17 (47)0.037
Used condoms inconsistently25/61 (41)7/16 (44)1.000
Had >2 sex partners16/61 (26)7/17 (41)0.244

*Values are no. positive/no. tested (%) unless otherwise indicated. PARV4, parvovirus 4; Ig, immunoglobulin; HCV, hepatitis C virus; HBsAg, hepatitis B surface antigen; HBc, hepatitis B core antigen;
†By Fisher exact test or Mann-Whitney U test. Values in boldface are significant.
‡At the time of interview.
§Closest to the sampling for PARV4 tests.

Conclusions

We developed IgG-, IgM-, and IgG-avidity–based PARV4 serodiagnostic procedures; studied high-prevalence cohorts by PCR; and analyzed HIV-infected IDUs for demographic and clinical correlations with PARV4 IgG positivity. Among healthy university students, none had PARV4 IgG, which is consistent with low baseline IgG prevalences of 0% and 2.8% for another EIA (6). The PARV4 IgG seroprevalence of 78% among HIV-infected IDUs represents a high incidence of PARV4, which reflects the lengthy history of drug use among socially marginalized IDUs during an HIV outbreak in Finland (7).

Two HCV-infected patients had PARV4 primary infections, as shown by increasing IgG levels, detectable IgM, low or borderline IgG avidity, and viral DNA in serum. These 4 findings are presented as diagnostic criteria for PARV4 primary infection. As estimated by known kinetics of B19 virus diagnostics (14), these 2 PARV4 infections probably occurred in 2005. During that time, neither patient had contacted local healthcare providers. Conversely, these 2 patients used intravenous drugs daily, and might not have sought medical care unless they were severely ill.

Because PARV4 IgG seroprevalence in group 1 was 0% in this study, in contrast to prevalences of 60% for B19 (12) and 96% for HBoV (9) in the same students, serologic cross-reactivity between PARV4 and the other human parvoviruses appears highly unlikely. Amino acid sequence similarity is <30% between B19 and PARV4 and ≈40% between HBoV and PARV4.

PCR-negative results for group 2, including 4 patients who were IgM positive, are evidence against viremic primary, chronic, and recurrent PARV4 infections. However, because of the relatively low sensitivity of this PCR, the data do not rule out low levels of viral DNA in blood.

Analysis of HIV-infected IDUs supports the view that in northern Europe PARV4 is primarily a blood-borne virus. No differences were seen for factors related to sexual activity. However, our sample size was too small to make this conclusion. In a recent PCR study, PARV4 genotype 3 was commonly found among infants in West Africa, and there was no evidence of parenteral exposure (15).

Using comprehensive serodiagnosis, we showed that PARV4 is ubiquitously present in IDUs in Finland and detected primary infections in 2 patients who had a full spectrum of diagnostic findings. Neither of these had sought medical help, which suggested that their primary infections may have been clinically mild or asymptomatic.

Suggested citation for this article: Lahtinen A, Kivelä P, Hedman L, Kumar A, Kantele A, Lappalainen MJ, et al. Serodiagnosis of primary infections with human parvovirus 4, Finland. Emerg Infect Dis [serial on the Internet]. 2011 Jan [date cited]. http://dx.doi.org/10.3201/eid1701.100750

This study was supported by the Helsinki University Central Hospital Research and Education, and Research and Development funds, the Sigrid Jusélius Foundation, the Medical Society of Finland, and the Academy of Finland (project 1122539).

Ms Lahtinen is a scientist at the Haartman Institute, Department of Virology of the University of Helsinki. Her research interests include clinical characteristics of parvoviruses.

ReferencesJones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:82306 10.1128/JVI.79.13.8230-8236.200515956568Simmonds P, Manning A, Kenneil R, Carnie FW, Bell JE Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis. 2007;13:1386818252117Lurcharchaiwong W, Chieochansin T, Payungporn S, Theamboonlers A, Poovorawan Y Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection. 2008;36:48891 10.1007/s15010-008-7336-418759058Longhi E, Bestetti G, Acquaviva V, Foschi A, Piolini R, Meroni L, Human parvovirus 4 in the bone marrow of Italian patients with AIDS. AIDS. 2007;21:14813 10.1097/QAD.0b013e3281e3855817589196Manning A, Willey SJ, Bell JE, Simmonds P Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus. J Infect Dis. 2007;195:134552 10.1086/51328017397006Sharp CP, Lail A, Donfield S, Simmons R, Leen C, Klenerman P, High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:111925 10.1086/60564619691429Kivelä P, Krol A, Simola S, Vaattovaara M, Tuomola P, Brummer-Korvenkontio H, HIV outbreak among injecting drug users in the Helsinki region: social and geographical pockets. Eur J Public Health. 2007;17:3816 10.1093/eurpub/ckl25217130140Kivelä PS, Krol A, Partanen AL, Ristola MA High prevalence of unprotected sex among Finnish HIV-positive and HIV-negative injecting drug users. Scand J Public Health. 2009;37:35763 10.1177/140349480910529019372233Söderlund-Venermo M, Lahtinen A, Jartti T, Hedman L, Kemppainen K, Lehtinen P, Clinical assessment and improved diagnosis of bocavirus-induced wheezing in children, Finland. Emerg Infect Dis. 2009;15:142330 10.3201/eid1509.09020419788810Kantola K, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O, Serodiagnosis of human bocavirus infection. Clin Infect Dis. 2008;46:5406 10.1086/52653218199037Tuke PW, Parry RP, Appleton H Parvovirus PARV4 visualization and detection. J Gen Virol. 2010;91:5414 10.1099/vir.0.014852-019846677Hedman L, Söderlund-Venermo M, Jartti T, Ruuskanen O, Hedman K Dating of human bocavirus infection with protein-denaturing IgG-avidity assays-secondary immune activations are ubiquitous in immunocompetent adults. J Clin Virol. 2010;48:448 10.1016/j.jcv.2010.02.00320227338Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion. 2007;47:105461 10.1111/j.1537-2995.2007.01235.x17524097Enders M, Schalasta G, Baisch C, Weidner A, Pukkila L, Kaikkonen L, Human parvovirus B19 infection during pregnancy–value of modern molecular and serological diagnostics. J Clin Virol. 2006;35:4006 10.1016/j.jcv.2005.11.00216332455Panning M, Kobbe R, Vollbach S, Drexler JF, Adjei S, Adjei O, Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis. 2010;16:11436 10.3201/eid1607.10002520587191